Keywords: Astellas, Mirabegron, Overactive bladder, OAB, USA, FDA, Advisory panel

FDA advisory panel backs Astellas OAB drug mirabegron

Article | 10 April 2012

Print This

The US subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) said last week that the Reproductive Health Drugs Advisory Committee ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in